For most people, the word "Wegovy" still calls to mind a weekly injection pen. But oral semaglutide tablets do exist in UK practice, and patients searching for a Wegovy pill are usually asking about one of two products: an oral Wegovy formulation licensed for weight management, or Rybelsus, an oral semaglutide tablet that is licensed for type 2 diabetes. This article walks through what's available, how oral semaglutide is dosed, how it compares to the injectable, and what UK prescribing actually looks like.

What "oral semaglutide" means

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that the body releases after eating, helping to slow stomach emptying, blunt appetite signals and improve blood glucose control. The molecule itself is the same whether it's delivered as a weekly injection or as a daily tablet — what changes is how it gets into the bloodstream.

The injectable formulation, which most UK patients know as the Wegovy pen, is given subcutaneously once a week. The oral formulation pairs semaglutide with an absorption enhancer called SNAC, which helps a small percentage of the dose cross the stomach lining. Because the absorption is modest and easily disrupted by food, the tablet has to be taken in a very specific way for the dose to work as intended.

Wegovy Oral and Rybelsus — what's different

The two oral semaglutide products UK patients are most likely to encounter are:

  • Wegovy Oral — an oral semaglutide formulation licensed for chronic weight management, dosed at higher strengths than Rybelsus to match the weight-management indication.
  • Rybelsus — an oral semaglutide tablet (3 mg, 7 mg and 14 mg) licensed for type 2 diabetes. Some UK clinicians have used it off-label for weight in selected patients, although it isn't licensed for that purpose and the higher doses studied for weight loss aren't matched by Rybelsus's licensed strengths.

Both tablets contain semaglutide; the difference is the licensed indication and the dose range each product offers. From a UK regulatory point of view, that distinction matters. A medicine prescribed within its licence sits inside the standard MHRA framework, while off-label use places additional clinical responsibility on the prescriber and needs a clear, documented rationale.

How oral semaglutide compares to the injectable pen

At trial level, mean weight loss with oral semaglutide at its highest studied dose tends to be lower than mean weight loss with the injectable Wegovy pen at its full maintenance dose of 2.4 mg once weekly. The injectable's most-studied dose produced average weight loss in the region of around 15% in the STEP-1 trial population at 68 weeks; oral semaglutide in the OASIS-1 trial produced a smaller mean reduction at its highest dose, although still meaningful and well above placebo.

Two practical caveats are worth saying out loud. First, these are population averages, not individual predictions — some patients respond more strongly to one format than the other. Second, the studied populations weren't identical, so head-to-head comparisons should be read carefully rather than as a simple ranking.

How the oral pill must be taken

Oral semaglutide is taken once daily, and the food-timing rule isn't optional. The licensed instructions are:

  • Take the tablet on an empty stomach, ideally first thing in the morning.
  • Swallow with no more than 120 ml of plain water (about half a glass) — not coffee, not juice, not flavoured water.
  • Wait at least 30 minutes before eating, drinking anything else, or taking other oral medication.
  • Swallow the tablet whole — don't crush, split or chew it.

This window matters because the absorption window for oral semaglutide is narrow. Food or other drinks within the 30-minute period substantially reduce how much of the dose enters the bloodstream, which means the medicine may simply not work as intended. For patients who travel, eat early breakfasts, or take multiple morning medications, this routine needs honest planning at the consultation stage.

What UK prescribing looks like

NHS access to semaglutide for weight management — whether oral or injectable — runs through specialist tier-3 or tier-4 weight-management services and is constrained against NICE eligibility criteria. In practice, the great majority of UK patients exploring semaglutide for weight loss do so privately through a UK-registered pharmacy.

A private consultation with a UK-registered clinician should cover medical history, current medications, BMI, blood pressure, and discussion of realistic outcomes and side-effect risks. NICE's overarching pathway for weight-management pharmacotherapy applies the same in principle to oral and injectable semaglutide: medicine sits alongside diet, physical activity and behavioural support, not in place of them. Our piece on how a weight-loss injection works covers the underlying GLP-1 mechanism in more depth.

Who tends to be suitable for the oral format

Suitability for oral semaglutide is a clinician-led decision, but a few patterns come up at consultation:

  • Needle aversion. Patients who genuinely cannot face a weekly injection sometimes prefer the daily tablet, accepting the trade-off of the food-timing rule and slightly lower trial-level weight loss.
  • Steady morning routines. Patients who naturally have an early, predictable morning are well placed to honour the 30-minute fasting window without disruption.
  • Patients on multiple morning medications. This needs more care — the 30-minute gap applies to other oral medications too, so polypharmacy patients may need their schedule reviewed.
  • Patients who want to try a daily rather than weekly cadence. Some patients prefer the psychology of a daily ritual rather than a weekly injection day.

For others, the injectable pen remains a better fit — particularly where trial-level weight loss is a high priority and the patient is comfortable with weekly self-injection. Our guide on which weight-loss injection works best compares the broader GLP-1 options.

Other GLP-1 options to be aware of

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist taken as a weekly injection, currently UK-licensed for weight management and type 2 diabetes. It is a different molecule from semaglutide and is not available in an oral formulation. For patients exploring options, your clinician will discuss whether semaglutide (oral or injectable), tirzepatide or a non-pharmacological route fits best.

Cost, supply and access in the UK

Oral semaglutide tablets sit at a similar prescription-only access level to the injectable. UK supply has been variable over the past two years, particularly for the higher injectable strengths, so patients should expect a clinician-led conversation about format choice that takes current supply into account, not just preference. Pricing for the oral format also varies and is not always cheaper than the injectable — it depends on dose, pack size and pharmacy.

Working with your Farmeci clinician

If you're weighing up an oral Wegovy pill against the injectable, or against staying with diet and lifestyle alone, the practical first step is a structured consultation. A UK-registered clinician will review your medical history, BMI and lifestyle, talk through the dosing rules honestly, and explain what each format is likely to mean for someone in your situation. There's no single "right" semaglutide format — there's the one that fits your circumstances, and that conversation is what the consultation is for. Your clinician will advise based on your individual circumstances.